Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase 3 study of TAK-279 in moderate-to-severe plaque psoriasis
2024-512496-12-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label trial of zasocitinib in plaque psoriasis (2 arms), sponsored by Takeda. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of serious adverse events. Planned start Apr 2025; status: authorised.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-512496-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512496-12-00.